Loquai C, Nashan D, Metze D, Beiteke U, Rüping K W, Luger T A, Grabbe S
Klinik und Poliklinik für Hautkrankheiten, Universitätsklinikum Münster.
Hautarzt. 2004 Feb;55(2):176-81. doi: 10.1007/s00105-003-0625-z.
The immune system plays an important role in the defense against malignant melanoma. Interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) are therapeutically used for unspecific stimulation of the immune system. After intralesional injections of these cytokines into cutaneous melanoma metastases, regression has been observed. In view of its immunomodulating effects, imiquimod appears as an additional promising therapeutic option for treatment of malignant tumors. In a case report, we present combined therapy with intralesional IL-2, pegylated IFN-alpha-2b and topical imiquimod 5% cream for disseminated cutaneous metastatic malignant melanoma stage IIIa. This therapy achieved an almost complete remission. In a treatment period of eight months, side effects remained tolerable. Histologically, both fibrosis and inflammation were found in the regressing lesions. After the end of therapy, no disease progression occurred during 11 months follow-up.
免疫系统在抵御恶性黑色素瘤中发挥着重要作用。α干扰素（IFN-α）和白细胞介素-2（IL-2）被用于非特异性刺激免疫系统的治疗。在将这些细胞因子瘤内注射到皮肤黑色素瘤转移灶后，观察到了消退情况。鉴于其免疫调节作用，咪喹莫特似乎是治疗恶性肿瘤的另一种有前景的治疗选择。在一份病例报告中，我们展示了瘤内注射IL-2、聚乙二醇化IFN-α-2b和外用5%咪喹莫特乳膏联合治疗IIIa期播散性皮肤转移性恶性黑色素瘤的情况。该治疗实现了几乎完全缓解。在八个月的治疗期内，副作用仍可耐受。组织学上，在消退的病灶中发现了纤维化和炎症。治疗结束后，在11个月的随访期间未出现疾病进展。
